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Primary gastrointestinal lymphoma is a common presenta-
tion of non-Hodgkin's lymphoma. The main controversy arises
when many aspects of its classification and management are
under discussion, particularly regarding roles for surgical
resection. The aim of this study was to evaluate clinicopatho-
logic characteristics and the therapeutic outcome of primary
gastrointestinal non-Hodgkin's lymphoma. We carried out a
retrospective analysis of 74 patients who were presented to our
center with histopathological diagnosis of primary gastro-inte-
stinal non-Hodgkin's lymphoma between 1990 and 2001. All
patients have been staged according to Lugano Staging Sys-
tem. For histopathological classification, International Working
Formulation was applied. The treatment choice concerning the
surgical or non-surgical management was decided by the ini-
tially acting physician. Treatment modalities were compared
using the parameters of age, sex, histopathological results,
stage, and the site of disease. Of the 74 patients, 31 were fe-
male and 43 were male, with a median age of 49 years (range
15-80). The stomach was the most common primary site and
was seen in 51 of 74 patients (68.9%). The intermediate and
high grade lymphomas constituted 91.9% of the all cases. In
a median follow-up of 29 months (range 2-128), 20 out of 74
patients died. There was a three year overall survival rate in
65.4% of all patients. The three year overall survival rate was
better in stage I and II1 patients who were treated with surgery
plus chemotherapy (+/-RT) than those treated with chemo-
therapy alone (93.7% vs. 55.6%, p<0.05). The stage and pres-
ence of B symptoms affected the disease free survival and
overall survival significantly, but the histopathologic grade
only affected the overall survival. On the basis of these results,
we suggest that surgical resection is necessary before chemo-
therapy in early stage (stage I and II1) patients with gastroin-
testinal non-Hodgkin's lymphomas because of the significant
survival advantage it would bring to the patient.
Key Words: Gastrointestinal non-Hodgkin's lymphoma, pro-
gnostic factors, clinicopathologic features, survival
INTRODUCTION
The gastrointestinal (GI) tract is the predomi-
nant site for extranodal non-Hodgkin's lymphoma
(NHL). Some reports have proposed that 2% to
9% of all gastric malignancies are primary malig-
nant lymphomas (MLs),
1,2 while in the small bowel
they constitute approximately 20% and in the
large bowel, 0.5% of all malignancies of the rema-
ining site.
3 Primary extranodal lymphoma consti-
tutes 25% of the NHL cases in North America and
up to 50% in parts of Europe, Turkey, and Middle
Eastern countries.
3-5 The incidence of GI lym-
phoma is higher in Eastern Countries than
Western Countries.
4-6 High grade histopathologic
types of gastric lymphomas are higher in Turkey
and Middle East Countries than Western Coun-
tries.
3-6
Treatment strategies for extranodal NHL are
well established, but there still remains much
debate and controversy regarding the optimal
approach for GI-NHL, particularly for gastric
lymphoma.
7-12 Surgery, radiotherapy (RT), and
chemotherapy (CT) have been used alone or in
various combinations.
13,14 Many studies have de-
monstrated sufficient tumor control with surgery
alone especially for gastric lymphomas due to an
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apparent tendency of these lymphomas staying in
a local stage for a prolonged time.
15-20 Surgery had
also been the only method for a long period in
medical history where the histological diagnosis
of GI-lymphoma can be established and an
accurate staging of these lymphomas can be
provided.
21,22 This approach has generally been
changed by the introduction of modern imaging
techniques such as computed tomography, ultra-
sound, endoscopy, and endoscopic ultrasound
including the technique of multiple biopsies from
GI-organs for the last 25 years.
Some attempts have been made for the last 15
years to increase the survival results of surgery
alone or by combining surgery and chemotherapy
and/or radiation therapy
23-25 as well as to pre-
serve the stomach by a conservative treatment
approach using RT and/or chemotherapy as the
first treatment modality without operation.
26,27 In
a number of studies, some chemotherapy regi-
mens have also been introduced for a curative
intent, particularly for high grade lymphoma, and
modern techniques of radiation therapy have been
proven effective in lymphomas.
28,29 Despite these
studies, there is a debate on the necessity of any
operation altogether, the requirement of com-
pleteness of operation
6 and other prognostic fac-
tors, such as histological grading, thickness of
tumor, intensity of chemotherapy, and radiation
dose.
23,30-35 To date, although several reports re-
garding treatment strategies of GI lymphomas
have been published, only a few of them are ran-
domized and prospective studies, and the sample
sizes of these reports are not sufficiently big.
13,36,38
The aim of this study is to evaluate clinico-
pathologic characteristics and therapeutic out-
comes of primary GI-NHLs.
MATERIALS AND METHODS
A retrospective study was carried out of pa-
tients who were presented to our center with a
histopathological diagnosis of primary GI-NHL
between 1990 and 2001. The medical charts of 92
patients were reviewed, and 74 of them were
available for the analysis of clinical data (char-
acteristics of all patients has been shown on Table
1). Treatment modalities have been compared
with age, sex, histopathological grade, B and T cell
histopathology, stage, and the site of disease. All
patients were staged according to Lugano Staging
System. For histopathological classification, Inter-
national Working Formulation was applied.
Treatment modalities
An initial surgical treatment decision was made
according to the surgeon's preference. In this
decision, the hematologist and/or the radiation
oncologist was not involved. Surgery (in which,
out of 24 patients total or subtotal gastrectomy, 9
patients had Roux-en-Y resection [This is a
choledocojejunostomy operation that performed
for biliary by-pass], 14 patients had tumor resec-
tion, 8 patients had debulking surgery) was per-
formed in 55 patients. Out of 55 patients, four
underwent radical surgery alone. After an initial
surgical resection, only chemotherapy (CT) was
performed in 44 patients, chemotherapy + radio-
therapy (RT) (3600 cGy total abdominal +/- 600
cGy boost RT to tumor bed) in two patients. CT
+ palliative surgery was performed in 5 patients.
Sixteen patients received CT alone, one patient
received CT + RT, and two patients got only sup-
portive care due to their poor performance status.
(Ed: highlight - Fragment. Make this into a
subtitle or into a sentence or erase altogether.)
If there was any residual disease and/or close-
positive surgical margin after surgery or if lymph
nodes that were 1 cm were detected by ultra-
sound, chemotherapy was administered addi-
tionally. If this regimen was not wholly successful,
then radiation treatment was administered. Fol-
lowing this treatment, if there was no response
with adjuvant treatment after surgery, a second
line of chemotherapy was administered.
Cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) and other antracycline
containing regimens are the most commonly used
regimens in 65 patients (treatment modalities for
all patients has been shown on Table 2). In gen-
eral, we administered 6-8 cycles of the classical
lymphoma regimen (CHOP-like regimens). In
early stage patients, if the involved field radiation
treatment was deemed necessary as a part of pre-
treatment in advance, chemotherapy was planned
in 4 cycles.Bulent Eser, et al.
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Statistical analysis
Overall survival was computed by the life table
method starting from diagnosis to the date of
death or last follow-up alive. The statistical sig-
nificance of observed differences was assessed by
the Log-rank test. The prognostic value of different
variables for the outcome was assessed by a uni-
variate analysis and a multivariate analysis using
the Cox regression model. A p value of <0.05 was
considered significant.
RESULTS
A total of 74 patients were evaluated, retrospec-
tively. Of the 74 patients, 43 were male and 31
were female with a median age of 49 years (range
15-80). The median age of the patients having
intestinal involvement was younger than those
with gastric involvement (median 43 vs. 52 years).
Stomach, small intestine, large intestine, and syn-
chronize multiple gastrointestinal site involve-
ment (ileocecal region was considered as small in-
testinal involvement) have occurred in 51 (68.9 %),
17 (23%), 2 (2.7%), and 4 (5.4%) patients respecti-
vely. According to the Lugano Staging System, 4
(5.4%) patients were in stage I, 19 (25.7%) in stage
II1, 15 (20.3%) in stage II2, 16 (21.6%) in stage IIE,
and 20 (27%) in stage IV (Table 1).
When our patients' initial symptoms were
evaluated, we observed that most patients had
gastrointestinal symptoms as seen in other se-
ries.
1,5,11,13 Initial signs and symptoms were as fol-
Table 1. Characteristics of 74 Patients with Gastro-
intestinal Non-Hodgkin's Lymphoma
Patients' characteristics No. of patients (%)
Age (yr) 74
60 24 (32.4)
< 60 50 (67.6)
Sex 74
F 31 (42)
M 43 (58)
Main symptoms 74
Gastrointestinal symptoms* 64 (86.4)
Haemorrhage 4 (5.4)
Perforation 3 (4)
Ileus 1 (1.4)
Diarrhea 1 (1.4)
Jaundice 1 (1.4)
B symptoms 74
Present 34 (46)
Not present 40 (54)
Site of disease 74
Stomach 51 (68.9)
Small bowel 17 (23)
Large bowel 2 (2.7)
Multiple site 4 (5.4)
Endoscopic/surgical findings 50
Vegetating mass 12 (24)
Ulceration 14 (28)
Ulcero-vegetating mass 21 (42)
Polyposis 3 (6)
Bulky disease ( 10 cm) 13 (17.6)
Histopathologic grade 74
Low grade 6 (8.1)
Intermediate grade 54 (73)
High grade 14 (18.9)
Histopathology 66
T cell 8 (12.1)
B cell 58 (87.9)
Lugano staging 74
Stage I 4 (5.4)
Stage II1 19 (25.7)
Stage II2 15 (20.3)
Stage IIE 16 (21.6)
Stage IV 20 (27)
*Nausea, vomiting and/or abdominal pain.
Tablo 2. Treatment Modalities of All Patients
Treatment modalities No. of patients (%)
Radical surgery alone 4 (5.4)
Surgery + chemotherapy 44 (59.5)
Surgery + chemotherapy + radiotherapy 2 (2.7)
Chemotherapy + palliative surgery 5 (6.8)
Chemotherapy + radiotherapy 1 (1.3)
Chemotherapy alone 16 (21.6)
Supportive care only 2 (2.7)
Total 74 (100.0)Therapeutic Outcomes of Gastrointestinal Non-Hodgki's Lymphomas
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lows: 64 patients had upper GI symptoms (nau-
sea, vomiting and/or abdominal pain), one had
jaundice, and another had diarrhea. Only eight
patients were admitted in emergency circum-
stances (three patients with perforation, four with
GI bleeding, and one with ileus). In most patients
who were diagnosed endoscopically or surgically,
a tumoral mass was detected, but solely gastric
ulceration was detected in 14 patients. This
finding shows that biopsy is critical in gastric
ulcerations in terms of lymphoma diagnosis. At
the time of diagnosis, 45.9% of the patients had B
symptoms.
Endoscopic and/ or surgical findings
In 50 patients, endoscopic and surgical reg-
istries have been obtained. According to these
registries, gastric ulceration was seen in 14
patients, vegetating masses in 12, ulcero-vege-
tating masses in 21, and multiple poliposis in
three. Thirteen patients illustrated a bulky (> 10
cm) disease.
Histopathology
In the patient population, high grade and ad-
vanced stage disease were highly frequent. Ac-
cording to Working Formulation, six patients had
low grade (8.1%), 54 had intermediate grade
(73%), and 14 had high grade (18.9%). Diffuse
large cell was the most frequent histopathological
type (67.5%). B and T cell immunohistochemical
staining had been performed in 66 patients and
the T cell markers were positive in eight patients
(Table 1).
Survival analysis
In a median follow-up of 29 months (range 2 -
128), 20 out of 74 patients died. The causes of
mortality were perforation in four, ileus in four,
hemorrhage in one, abdominal infection in one,
acute myocardial infarction in one, and progres-
sive disease in nine patients. A three-year overall
survival rate (OS) was 65.4% in all patients (Fig.
1). A three-year OS was 83% in patients with low
grade histopathology, 68% in intermediate grade
patients, and 44% in high grade lymphoma
patients (Fig. 2). While the three-year OS pro-
bability was 85.7% in stage I and II1 patients, this
probability was only 25.5% in stage IV (Fig. 3).
We evaluated the effect of age, sex, stage, pres-
ence of B symptoms, histopathologic grade, and
Fig. 1. Overall survival of all gastrointestinal non-Hodgkin's lymphoma patients.Bulent Eser, et al.
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T cell markers positivity on survival. According to
the univariate analysis, advanced stage, high
grade histopathology, and the presence of B
symptoms negatively affected the overall survival
(OS) rate (p < 0.05) (Fig. 2 - 4). According to the
Cox regression multivariate analysis, only the
advanced stage was implicated in the overall sur-
vival rate (p = 0.01) (Table 3). According to the
Fig. 2. The effect of histopathological grades on overall survival in low, intermediate and high grade gastrointestinal
non-Hodgkin's lymphoma.
Fig. 3. The overall survival of early and advanced stages gastrointestinal non-Hodgkin's lymphoma.Therapeutic Outcomes of Gastrointestinal Non-Hodgki's Lymphomas
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univariate analysis, the presence of B symptoms
and the condition of being in the advanced stage
have negatively affected the disease free survival
(DFS) (p<0.05). According to the Cox regression
multivariate analysis, the advanced stage has
significantly and negatively affected the DFS (p =
0.02), and the presence of B symptoms affected
DFS almost to a significant extent (p = 0.04) (Table
4).
The effect of surgery on survival
We searched the effect of surgery in patients
with completely resectable early stage (stage I and
II1) and unresectable-advanced stage (stage II2,
IIE, IV) on overall survival and progression free
survival. When observing the features of the two
groups, there was no difference between the two
groups in terms of histopathological and clinical
variables (grade, age, and B symptoms).
Serious treatment related complications
Treatment related death was observed in four
patients. Perforation was the cause of death in one
(which was chemotherapy related in an early
Fig. 4. The effect of the presence of B symptoms on overall survival.
Table 3. Cox Multivariate Analysis for Overall Survival
Parameters Odds ratio 95% CI p value
Sex 1.1147 0.41 - 3.05 NS
Localisation 1.5955 0.56 - 4.59 NS
Stage 2.4329 1.20 - 4.92 .01
Grade 2.0839 0.84 - 5.17 NS
Age (< 60 or 60 yr) 0.8770 0.32 - 2.40 NS
Surgery 1.0781 0.41 - 2.81 NS
B symptoms positivitiy 2.1900 0.77 - 6.24 NSBulent Eser, et al.
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stage patient), and the remaining three died due
to intestinal obstruction (one of them was a che-
motherapy related complication in an early stage
patient, one patient died from surgical compli-
cation, and the last one died from a chemotherapy
complication which was in an advanced stage
patient).
The three-year OS rate was better in stage I and
II1 patients who were treated with surgery plus
chemotherapy (+/-RT) than those treated with
chemotherapy alone (93.7% vs. 55.6%, p = 0.027)
(Fig. 5). In advanced stage diseases, performing
surgery seemed to be a disadvantage, but there
was no statistically significant difference (53.5% vs
64.8%, p = 0.9)(Fig. 6).
In the early stage, for those patients who
underwent surgery in addition to chemotherapy,
the overall response rate (complete response +
partial response), 3-year DFS rate, and 3-year OS
rate are statistically higher than those who
received chemotherapy alone (Table 5). In the
advanced stage, there were no differences in
terms of 3-year DFS and OS between the two
groups (Table 6).
Table 4. Cox Multivariate Analysis for Progression Free Survival
Parameters Odds ratio 95% CI p value
Sex 1.1927 0.49 - 2.91 NS
Localisation 0.9020 0.34 - 2.38 NS
Stage 2.0050 1.12 - 3.60 .02
Grade 1.5532 0.68 - 3.54 NS
Age (< 60 or 60 yr) 0.9430 0.40 - 2.23 NS
Surgery 1.2313 0.53 - 2.85 NS
B symptoms positivitiy 2.6535 1.06 - 6.61 .04
Fig. 5. The effect of surgery on the overall survival in stage I-II1 gastrointestinal non-Hodgkin's lymphoma.Therapeutic Outcomes of Gastrointestinal Non-Hodgki's Lymphomas
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DISCUSSION
Gastrointestinal lymphomas are the most com-
mon type of primary extranodal lymphomas.
1,2,13,30,39 The stomach is the main affected site with
a frequency ranging from 37.8% to 86% (mean,
59.8%).
13,30,32,39 In our series of 74 patients who
were reviewed retrospectively, the stomach is the
main site in approximately 69% of the cases (Table
1), which is clearly higher than in other publica-
tions. But compared to the literature, the median
age of the patients in our series with primary in-
testinal NHL is younger than that of gastric
lymphoma (43 vs 52 years).
5,38,40-42 Also, there is a
higher male predominance in our series (male-to-
female ratio: 1.3/1).
Table 6. The Effect of Surgery on Outcomes in Advanced Stage of Disease
Outcomes Chemotherapy alone Surgery + Chemotherapy p value
Response rate, % 50 48 NS
3-year overall survival rate, % 64.8 53.5 NS
3-year progression free survival rate, % 55.0 39.8 NS
Fig. 6. The effect of surgery on the overall survival in advanced stages of gastrointestinal non- Hodgkin's lymphoma.
Table 5. The Effect of Surgery on Outcomes in Early Stage of Disease
Outcomes Chemotherapy alone Surgery + Chemotherapy p value
Response rate, % 67 100 0.015
3-year overall survival rate, % 55.6 93.7 0.03
3-year progression free survival rate, % 55.6 84.4 0.05Bulent Eser, et al.
Yonsei Med J Vol. 47, No. 1, 2006
To describe the extent of the disease, most
authors applied the Ann Arbor classification or
its modification by Musshoff or Rohatiner.
9,43 Lo-
calized stages (IE, IIE) are predominant in gastric
lymphoma. Two authors report 84% and 87%,
13,30
which is comparable to our data (73%), whereas
published registry data are lower (68%).
40 The
rate for localized intestinal lymphoma is slightly
lower with a range of 52% to 80% (in our series,
this was 53%). Only one study states the distri-
bution of stages in different sites of intestinal
lymphoma 30 and reports a percentage in the
localized disease (stages IE and IIE) of 78% for
the small bowel and 80% for the ileocecal region.
The majority of GI lymphoma is of high grading
in all series, but the usage of different histologic
classifications makes the comparison difficult,
especially in intestinal lymphomas. So far, the
classification by Isaacson et al.
44 has been used in
only two publications,
45,46 but both reports are
restricted to localized gastric lymphoma. In only
one published major prospective study, the
Working Formulation had been primarily ap-
plied.
13 In the retrospective analysis of the British
National Lymphoma Investigation, the Working
Formulation was used in most cases.
14
Appropriate management of primary GI lym-
phoma is still controversial. The most contro-
versial issue on the treatment of GI lymphomas is
whether or not the surgical treatment approach is
necessary. Although there are a lot of studies on
the advantage of surgical treatment in stage I-II1
disease, most of these are non- randomized and
have conflicting results.
3,14,17-19,36 Another issue is
to what extent surgery is necessary.
47 On the other
hand, surgery may delay the use of chemo-
therapy, causes some morbidity, and also has a
mortality rate of up to 10%. Currently, several
series have reported patients who have been
treated with surgery and chemotherapy; with
biopsy, chemotherapy, and irradiation; or with
biopsy and irradiation.
27,48,49 In an analysis by the
Danish Lymphoma Study Group of 175 gastric
lymphomas, 105 were localized.
32 Sixty-seven of
105 patients had surgery. The authors found no
role for surgery in altering the overall or relapse-
free survival rates. In completely resectable early
stage patients, surgery had more of an advantage.
On the contrary, surgery had no survival advan-
tage in advanced stage patients, and might even
have some disadvantage. In our series, eight
patients out of 20, died in the first four months
of treatment. Four of them died due to surgical
complications (one intraabdominal infection, two
perforation, and one ileus), and the remaining
four died because of chemotherapeutic complica-
tions (two perforation, two ileus). Although it was
stated that surgery has the advantage of total
tumor removal and limits the risk of hemorrhage
and perforation,
17-19 this was not supported by the
analysis of our patients. If primary intestinal
lymphoma is diagnosed at laparotomy, surgical
resection can be preferred. In the advanced dis-
ease, where resection is not technically feasible,
treatment consists of anthracycline-based chemo-
therapy followed, in some cases, by radiation
therapy. However, due to the absence of ran-
domized trials, the optimal treatment strategy is
not known.
47 In our series, 17 patients were diag-
nosed at laparotomy, and the tumors were re-
sected in 14 of them.
Current clinical trials are being proposed in
order to treat patients with clearly resectable
disease with surgery plus chemotherapy versus
chemotherapy plus radiation therapy. Patients
with unresectable disease were randomly as-
signed to receive chemotherapy alone versus
chemotherapy plus irradiation, and chemother-
apy was more intense in these patients.
50
The outcomes reported in the literature vary
depending on the extent and histology of the
disease. Most publications have stated a survival
rate (SR) for all intestinal lymphomas together
with a range of 24% to 67%, and the estimated
5-year SR was 67.1% in our series and 67% in
another prospective study.
13 In a large series of
intestinal lymphomas, Domizio and co-workers
38 documented a 5-year SR of 75% for patients
with low-grade B-cell lymphomas and only 25%
for those with T-cell tumors; the poor outcome
for intestinal T-cell lymphoma was also docu-
mented in the British and Danish experience.
14,32
In all reports, the number of intestinal lymphomas
is small. To allow for a better comparison,
different parts of the intestine should be clearly
defined which from our point of view is of
importance especially for lymphomas of the
ileocecal region that seems to have a prognosisTherapeutic Outcomes of Gastrointestinal Non-Hodgki's Lymphomas
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comparable to that of gastric lymphoma. Ileocecal
NHL can be diagnosed by endoscopy, and a fact
raises the question of whether surgery is really
necessary for a treatment. In conclusion, it seems
that intestinal lymphomas has raised less interest
in the past but should become the aim of pro-
spective studies.
36
In general, there is a demand for a stan-
dardized staging system. Therefore, we proposed
to use the basic framework of the Ann Arbor
classification 51, incorporating Rohatiner's sub-
division of stage II (Lugano Staging System).
11
Stage I included patients with lymphoma con-
fined to the gastrointestinal tract as the single
primary site or multiple, non-contiguous lesions.
Stage II lymphoma was extended into the
abdomen from the primary site involving local
(perigastric/mesenteric) (stage II1) or distant
(celiac, para-aortic, paracaval or retroperitoneal)
(stage II2) lymp nodes or penetrated into serosa
involving adjacent organs or tissues (stage IIE).
Finally, stage IV patients had a disseminated ex-
tranodal involvement of lymphoma or a gastro-
intestinal lesion with supradiaphragmatic nodal
involvement. Although the Revised European-
American Lymphoma (REAL) classification and
the World Health Organization (WHO) classifi-
cation included extranodal lymphomas for the
first time, the detailed subclassification of high-
grade lymphoma of MALT type as published by
Isaacson et al.
8 has not been taken into account
because of its clinical implications.
52 However,
even in WHO and REAL classifications, ex-
tranodal lymphomas are included, and there are
no standard classifications for the high grade GI
lymphomas.
In summary, GI-NHL is a heterogeneous dis-
ease depending on the site of origin within the GI
tract. Primary gastric lymphoma is by far the
largest group, which has its own distinct histo-
pathologic and clinical features. Stage is the most
important prognostic factor, with a significantly
better survival for the localized disease. The
frequency of gastric lymphoma in stages IE and
IIE allows for an analysis of the treatment strategy
that concerns the combined surgical and conser-
vative treatment versus conservative treatment
alone. As for the analysis of the advanced disease
in lymphoma of the stomach, as well as in intes-
tinal NHL, a larger number of patients is required.
In conclusion, this study shows that gastro-
intestinal complications are the most important
cause of mortality in patients with GI lymphomas.
Poor prognostic factors were more frequent in our
patients than that of Western Countries. Surgical
resection may be considered before chemotherapy
in patients with early stage (stage I and II1) GI
lymphomas because this leads to a good survival
probability. On the other hand, it seems that sur-
gery has no advantage in the advanced disease,
and by contrast, due to the adverse effect of
surgery in these patients, debulking surgery is
also not suggested.
REFERENCES
1. Freeman C, Berg JW, Cutler SJ. Occurence and pro-
gnosis of extranodal lymphomas. Cancer 1972;29:252-
60.
2. Lee Y-TN, Spratt JS. Gastrointestinal malignant lym-
phomas. In: Malignant Lymphoma, Nodal and Extra-
nodal Diseases (Modern Surgical Monograph). New
York: Grune and Stratton; 1974. p.229-60.
3. Dincol D, Icli F, Erekul S, Gunel N, Karaoguz H,
Demirkazik A. Primary gastrointestinal lymphomas in
Turkey: a retrospective analysis of clinical features and
results of treatment. J Surg Oncol 1992;51:270-3.
4. Sarpel SC, Paydas S, Tuncer I, Varinli S, Koksal M,
Akoglu T. Non-Hodgkin's lymphomas in Turkey.
Cancer 1988;62:1653-7.
5. Otter R, Bieger R, Kluin PM, Hermans J, Willemze R.
Primary gastrointestinal non-Hodgkin's lymphoma in a
population-based registry. Br J Cancer 1989;60:745-50.
6. Salem P, Anaissie E, Allam C, Geha S, Hashimi L,
Ibrahim N, et al. Non-Hodgkin's lymphomas in the
Middle East. A study of 417 patients with emphasis on
special features. Cancer 1986;58:1162-6.
7. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F,
Kelenyi G, et al. Updated Kiel classification for
lymphomas. Lancet 1988;1:292-3 (letter).
8. Isaacson P, Wright DH. Extranodal malignant lym-
phoma arising from mucosa-associated lymphoid
tissue. Cancer 1984;53:2515-24.
9. Musshoff K. Klinische Stadieneinteilung der Nicht-
Hodgkin-Lymphome. Strahlentherapie 1977;153:218-21.
10. Schmidt WP, Schmitz N, Sonnen R. Conservative
management of gastric lymphoma: the treatment option
of choice. Leuk Lymphoma 2004;45:1847-52.
11. Rohatiner A, d'Amore F, Coiffier B, Crowther D,
Gospadarowicz M, Isaacson P, et al. Report on a work-
shop convened to discuss the pathological and staging
classifications of gastrointestinal tract lymphoma. AnnBulent Eser, et al.
Yonsei Med J Vol. 47, No. 1, 2006
Oncol 1994;5:397-400.
12. Shimodaira M, Tsukamoto Y, Niwa Y, Goto H, Hase S,
Hayakawa T, et al. A proposed staging system for
primary gastric lymphoma. Cancer 1994;73:2709-15.
13. Ruskone-Fourmestraux A, Aegerter P, Delmer A,
Brousse N, Galian A, Rambaud JC, et al. Primary
digestive tract lymphoma: A prospective multicentric
study of 91 patients-Groupe d'Etude des Lymphomes
Digestifs. Gastroenterology 1993;105:1662-71.
14. Morton JE, Leyland MJ, Vaughan Hudson G, Vaughan
HB, Anderson L, Bennett MH, et al. Primary gastro-
intestinal non-Hodgkin's lymphoma: A review of 175
British National Lymphoma Investigation cases. Br J
Cancer 1993;67:776-82.
15. Dawson IMP, Cornes JS, Morson BC. Primary malig-
nant lymphoid tumours of the intestinal tract. Br J Surg
1961;49:80-9.
16. Lim FE, Hartmann AS, Tan EGC, Cady B, Meissner
WA. Factors in the prognosis of gastric lymphoma.
Cancer 1977;39:171-2.
17. Baildam AD, Williams GT, Schofield PF. Abdominal
lymphoma-the place for surgery. J R Soc Med 1986;82:
657-60.
18. Feil W, Wenzl E, Radaskiewicz T, Schiessel R. Non
Hodgkin lymphoma of the stomach: Surgical therapy
and prognosis. Klin Wschr 1987;99:426-30.
19. Verreet PR, Borchard F, Stöltzing H, Thon K, Röher
HD. Status of gastrectomy in the multi-modality
therapy concept of primary non-Hodgkin's lymphoma
of the stomach. Langenbecks Arch Chir 1990;375:151-5.
20. Brands F, Monig SP, Raab M. Treatment and prognosis
of gastric lymphoma. Eur J Surg 1997;163:803- 13.
21. Brooks JJ, Enterline HT. Primary gastric lymphomas: A
clinicopathologic study of 58 cases with long-term
follow-up and literature review. Cancer 1983;51:701-11.
22. Nakamura S, Matsumoto T, Lida M, Yao T, Tsuneyoshi
M. Primary gastrointestinal lymphoma in Japan: a
clinicopathologic analysis of 455 patients with special
reference to its time trends. Cancer 2003;97:2462-73.
23. Dragosics B, Bauer P, Radaskiewicz T. Primary gastro-
intestinal non-Hodgkin's lymphomas. A retrospective
clinicopathologic study of 150 cases. Cancer 1985;55:
1060-73.
24. Gospodarowicz MK, Bush RS, Brown TC, Chua T.
Curability of gastrointestinal lymphoma with com-
bined surgery and radiation. Int J Radiat Oncol Biol
Phys 1983;9:3-9.
25. Chung HC, Roh JK, Koh EH, Kim JH, Hahn JS, Park
IS, et al. Comparison of adjuvant radiotherapy and
chemoradiotherapy following surgery in stage IE and
IIE primary gastrointestinal tract non-Hodgkin's lym-
phoma. Yonsei Med J 1990;31:144-55.
26. Maor MH, Maddux B, Osborne BM, Fuller LM,
Sullivan JA, Nelson RS, et al. Stages IE and IIE non-
Hodgkin's lymphoma of the stomach: Comparison of
treatment modalities. Cancer 1984;54:2330-7.
27. Maor MH, Velasquez WS, Fuller LM, Silvermintz KB.
Stomach conservation in stages IE and IIE gastric non-
Hodgkin's lymphoma. J Clin Oncol 1990;8:266-71.
28. Gobbi PG, Dionigi P, Barbieri F, Corbella F, Bertoloni
D, Grignani G, et al. The role of surgery in the multi-
modal treatment of primary gastric non-Hodgkin's
lymphomas. Cancer 1990;65:2528-36.
29. Sonnen R, Calavrezos A, Grimm HA, Kuse R. Com-
bined conservative treatment of localized stomach
lymphoma. Dtsch Med Wochenschr 1994;119:863-8.
30. Azab MB, Henry-Amar M, Rougier P, Bognel C,
Theodore C, Carde P, et al. Prognostic factors in pri-
mary gastrointestinal non-Hodgkin's Lymphoma. A
multivariate analysis, report of 106 cases, and review
of the literature. Cancer 1989;64:1208-17.
31. Herrmann R, Panahon AM, Barcos MP, Walsh D,
Stutzman L. Gastrointestinal involvement in non-
Hodgkin's lymphoma. Cancer 1980;46:215-22.
32. Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the
gastrointestinal tract: A study of 117 cases presenting
with gastrointestinal disease. Cancer 1978;42: 693-707.
33. Shiu MH, Karas M, Nisce L, Lee BJ, Filippa DA,
Lieberman PH. Management of primary gastric lym-
phoma. Ann Surg 1982;195:196-202.
34. Shiu MH, Nisce LZ, Pinna A, Straus DJ, Tome M,
Filippa DA, et al. Recent results of multimodal therapy
of gastric lymphoma. Cancer 1986;58:1389-99.
35. Steward WP, Harris M, Wagstaff J, Scarffe JH, Deakin
DP, Todd DH, et al. A prospective study of the
treatment of high-grade histology non-Hodgkin's
lymphoma involving the gastrointestinal tract. Eur J
Cancer Clin Oncol 1985;21:1195-200.
36. Koch P, del Valle F, Berdel WE, Willich NA, Reers B,
Hiddemann W, et al. Primary gastrointestinal non-
Hodgkin's lymphoma: I. Anatomic and histologic dis-
tribution, clinical features, and survival data of 371
patients registered in the German Multicenter Study
GIT NHL 01/92. J Clin Oncol 2001;19:3861-73.
37. Krugmann J, Dirnhofer S, Gschwendtner A, Berresheim U,
Greil R, Krugmann K, et al. Primary gastrointestinal
B-cell lymphoma. A clincopathological and immuno-
histochemical study of 61 cases with an evaluation of
prognostic parameters. Pathol Res Pract 2001;197:385-
93.
38. Haber DA, Mayer RJ. Primary gastrointestinal lym-
phoma. Semin Oncol 1988;15:154-69.
39. Liang R, Todd D, Chan TK, Chiu E, Lie A, Kwong YL,
et al. Prognostic factors for primary gastrointestinal
lymphoma. Hematol Oncol 1995;13:153-63.
40. D'Amore F, Brincker H, Gronbaek K, Thorling K,
Pedersen M, Jensen MK, et al. Non-Hodgkin's lym-
phoma of the gastrointestinal tract: A population-
based analysis of incidence, geographic distribution,
clinicopathologic presentation features, and prognosis-
Danish Lymphoma Study Group. J Clin Oncol 1994;12:
1673-84.
41. Hansen PB, Vogt KC, Skov RL, Pedersen-Bjergaard U,
Jacobsen M, Ralfkiaer E, et al. Primary gastrointestinal
non-Hodgkin's lymphoma in adults: A population-
based clinical and histopathologic study. J Intern MedTherapeutic Outcomes of Gastrointestinal Non-Hodgki's Lymphomas
Yonsei Med J Vol. 47, No. 1, 2006
1998;244:71-8.
42. Gurney KA, Cartwright RA, Gilman EA. Descriptive
epidemiology of gastrointestinal non-Hodgkin's lym-
phoma in a population-based registry. Br J Cancer 1999;
79:1929-34.
43. Mafune KI, Tanaka Y, Suda Y, Izumo T. Outcome of
patients with non-Hodgkin's lymphoma of the stomach
after gastrectomy: clinicopathologic study and reclas-
sification according to the revised European- American
lymphoma classification. Gastric Cancer 2001;4:137-43.
44. Isaacson PG, Spencer J, Wright DH. Classifying pri-
mary gut lymphomas. Lancet 1988;2:1148-9 (letter).
45. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointesti-
nal malignant lymphomas of the mucosa-associated
lymphoid tissue: Factors relevant to prognosis. Gastro-
enterology 1992;102:1628-38.
46. Cogliatti SB, Schmid U, Schumacher U, Eckert F,
Hansmann ML, Hedderich J, et al. Primary B-cell gas-
tric lymphoma: A clinicopathological study of 145
patients. Gastroenterology 1991;101:1159-70.
47. Gospodarowicz MK, Wasserman TH. Non-Hodgkin's
Lymphoma. In: Perez CA and Brady LW, editors.
Principles and practice of radiation oncology. New
York: Lippincott-Raven; 1998. p.2000-1.
48. Valicenti RK, Wasserman TH, Monyak DJ, Kucik NA.
Non-Hodgkin Lymphoma: Whole- abdomen irradia-
tion as an adjuvant to chemotherapy. Radiology 1994;
192:571-6.
49. Taal BG, Burgers JM, van Heerde P, Hart AA, Somers
R. The clinical spectrum and treatment of primary
non-Hodgkin's lymphoma of the stomach. Ann Oncol
1993;4:834-9.
50. Willich NA, Reinartz G, Horst EJ, Delker K, Reers B,
Hiddemann W, et al. Operative and conservative
management of primary gastric lymphoma: Interim
results of a German multicenter study. Int J Radiat
Oncol Biol Phys 2000;46:895-901.
51. Koch P, Hiddemann W. Therapy of gastric lymphoma
of MALT type, including antibiotics. In: Mason DY,
Harris NL, editors. Human lymphoma: Clinical impli-
cations of the REAL classification. London: United
Kingdom, Springer-Verlag; 1999. p.201-8.